Dynavax Technologies Corporation

Company Overview

Business Model: Dynavax Technologies Corporation is a commercial stage biopharmaceutical company focused on developing and commercializing innovative vaccines to protect against infectious diseases. The company's strategy centers on maximizing the utilization of its HEPLISAV-B hepatitis B vaccine, expanding its portfolio of innovative vaccine candidates leveraging its proprietary CpG 1018 adjuvant technology, and identifying strategic growth opportunities through commercial and research collaborations.

Market Position: HEPLISAV-B is the only two-dose hepatitis B vaccine for adults approved in the United States, the European Union, and the United Kingdom. In Phase 3 trials, HEPLISAV-B demonstrated faster and higher rates of protection (95% seroprotection rate in HBV-23 trial) with two doses in one month compared to a three-dose, six-month schedule of Engerix-B (81% seroprotection rate), with similar safety profiles. The estimated total market share for HEPLISAV-B in the United States increased to approximately 44% at the end of 2024, up from approximately 42% at the end of 2023. The company anticipates the United States adult hepatitis B vaccine market to expand to a peak of over $900.0 million in annual sales by 2030, with HEPLISAV-B expected to achieve at least 60% total market share. The CpG 1018 adjuvant, a yeast-derived product, is highlighted for its established tolerability profile, ability to enhance immune response without excessive reactogenicity, and its role in driving Th1 immune responses and durable antibody levels.

Recent Strategic Developments:

• HEPLISAV-B Commercialization: Received marketing authorization in the United Kingdom in March 2023. Commercial shipments in Germany commenced in May 2022 through a commercialization agreement with Bavarian Nordic. The United States Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices published a universal recommendation in April 2022 for hepatitis B vaccination for all adults aged 19-59.
• Pipeline Advancement:
  • Shingles Vaccine Program (Z-1018): Initiated a randomized, active-controlled, dose escalation, multicenter Phase 1/2 trial in June 2024 to evaluate safety, tolerability, and immunogenicity compared to Shingrix in 441 healthy adults aged 50 to 69. Enrollment was completed in the fourth quarter of 2024, with top-line immunogenicity and safety data anticipated in the third quarter of 2025.
  • Plague Vaccine Program (rF1V with CpG 1018): Completed a Phase 2 clinical trial in late 2024 in collaboration with and fully funded by the U.S. Department of Defense. A new agreement for approximately $30.0 million was executed through the first half of 2027 to support additional Phase 2 clinical and manufacturing activities, with a new Phase 2 clinical trial expected to initiate in the third quarter of 2025.
  • HEPLISAV-B for Adults on Hemodialysis: Received a Complete Response Letter from the FDA in May 2024 for a supplemental Biologics License Application for a four-dose regimen. The company is exploring an observational retrospective cohort study and expects to resubmit the sBLA in 2025.
  • Tdap Vaccine Program (Tdap-1018): Discontinued development in November 2024, as results from a long-term Phase 1 extension study did not demonstrate a commercially differentiated profile.

Geographic Footprint: Dynavax Technologies Corporation has its corporate headquarters in Emeryville, California, and maintains an office and manufacturing facility in Düsseldorf, Germany. The company has marketing authorization for HEPLISAV-B in the United States, the European Union, and the United Kingdom, with commercialization efforts in the United States and Germany. It also has subsidiaries including Dynavax GmbH in Germany, Dynavax India LLP in India, and a branch in Italy.

Financial Performance

Revenue Analysis

Profitability Metrics:

• Gross Margin: 82.2% (2024)
• Operating Margin: -1.5% (2024)
• Net Margin: 9.8% (2024)

Investment in Growth:

• R&D Expenditure: $61.6 million (22.2% of revenue)
• Capital Expenditures: $6.4 million
• Strategic Investments: Increased clinical expenses for the shingles vaccine program's Phase 1/2 trial. A new agreement with the U.S. Department of Defense for approximately $30.0 million through the first half of 2027 to support additional Phase 2 clinical and manufacturing activities for the plague vaccine candidate.

Key Product & Pipeline Analysis

HEPLISAV-B [Hepatitis B Vaccine (Recombinant), Adjuvanted]

Financial Performance:

• Revenue: $268.4 million (+26% YoY)
• Operating Margin: Not separately disclosed.
• Key Growth Drivers: The increase was primarily driven by a $40.3 million increase due to higher volume from continued market share gains in the United States (particularly in integrated delivery networks and retail segments) and growth in the United States hepatitis B vaccine market following the Advisory Committee on Immunization Practices universal recommendation. Approximately $14.8 million of the increase was due to a higher net sales price.

Product Portfolio:

• HEPLISAV-B is the only two-dose hepatitis B vaccine for adults approved in the United States, the European Union, and the United Kingdom.
• It combines CpG 1018 adjuvant and recombinant hepatitis B surface antigen (rHBsAg).
• The company primarily uses a pre-filled syringe presentation of the vaccine.

Market Dynamics:

• The United States adult hepatitis B vaccine market is expected to expand to a peak of over $900.0 million in annual sales by 2030, with HEPLISAV-B projected to achieve at least 60% total market share.
• Competition includes Engerix-B and Twinrix from GlaxoSmithKline plc, Recombivax-HB from Merck & Co., and PreHevbrio from VBI Vaccines Inc.
• The Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices universal recommendation for adults aged 19-59 has significantly expanded the target population.

Strategic Initiatives:

• Developing a four-dose HEPLISAV-B vaccine regimen for adults on hemodialysis. A Complete Response Letter was received from the FDA in May 2024, and the company expects to resubmit its supplemental Biologics License Application in 2025 after exploring an observational retrospective cohort study.

CpG 1018 Adjuvant Supply

Financial Performance:

• Revenue: $0 (2024 and 2023).
• Operating Margin: Not separately disclosed.
• Key Growth Drivers: Potential for new demand if collaborators utilize existing inventory or new programs advance to commercialization. The company previously generated significant revenue ($587.7 million in 2022) from CpG 1018 adjuvant supply during the COVID-19 pandemic.

Product Portfolio:

• Proprietary Toll-like Receptor 9 (TLR9) agonist adjuvant.
• Used in HEPLISAV-B and other vaccine candidates in development.

Market Dynamics:

• CpG 1018 adjuvant has an established tolerability profile and has demonstrated its ability to enhance immune responses without excessive reactogenicity.
• It drives specific T Helper 1 (Th1) immune responses and protective antibody production.
• Being yeast-derived, it is considered more sustainable than other adjuvants.

Shingles Vaccine Program (Z-1018)

Financial Performance:

• R&D expenses increased primarily due to increased clinical expenses related to the initiation and completion of patient enrollment in a Phase 1/2 clinical trial in 2024.
• Operating Margin: Not separately disclosed.
• Key Growth Drivers: Aims to develop a shingles vaccine with improved tolerability and comparable efficacy to the current standard of care, leveraging CpG 1018 adjuvant's ability to generate high levels of CD4+ T-cells.

Product Portfolio:

• Investigational vaccine candidate for the prevention of shingles in adults aged 50 and older.
• Comprised of glycoprotein E (gE) plus CpG 1018 adjuvant.

Recent Developments:

• A Phase 1/2 clinical trial evaluating safety, tolerability, and immunogenicity of Z-1018 compared to Shingrix in 440 healthy adults aged 50 to 69 was initiated in June 2024, with enrollment completed in the fourth quarter of 2024.
• Top-line immunogenicity and safety data are anticipated in the third quarter of 2025.

Plague Vaccine Program (rF1V with CpG 1018)

Financial Performance:

• R&D expenses decreased in 2024 due to the completion of the Phase 2 clinical trial, but a new agreement for approximately $30.0 million through the first half of 2027 was executed with the U.S. Department of Defense.
• Operating Margin: Not separately disclosed.
• Key Growth Drivers: Fully funded by the U.S. Department of Defense, aiming to develop an improved plague vaccine.

Product Portfolio:

• A plague (rF1V) vaccine candidate adjuvanted with CpG 1018.

Recent Developments:

• The Phase 2 clinical trial evaluating immunogenicity, safety, and tolerability in adults was completed in late 2024.
• A new agreement with the U.S. Department of Defense for approximately $30.0 million through the first half of 2027 will support additional Phase 2 clinical and manufacturing activities, including a Phase 2 clinical trial expected to initiate in the third quarter of 2025.

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: In November 2024, the Board of Directors authorized a share repurchase program of up to $200.0 million. An accelerated share repurchase agreement with Goldman Sachs & Co. LLC resulted in a $100.0 million payment for the repurchase of 6,149,116 shares of common stock.
• Dividend Payments: Dynavax Technologies Corporation has never paid cash dividends on its common stock and does not anticipate paying any in the foreseeable future, expecting to retain future earnings for business operations and expansion.
• Future Capital Return Commitments: As of December 31, 2024, $100.0 million remained available for future repurchases under the authorized program.

Balance Sheet Position:

• Cash and Equivalents: $95.9 million (as of December 31, 2024)
• Total Debt: $223.9 million (Convertible Notes, net of debt discount, as of December 31, 2024)
• Net Cash Position: -$128.0 million (Net Debt)
• Credit Rating: Not disclosed.
• Debt Maturity Profile: The 2.50% Convertible Senior Notes have an aggregate principal amount of $225.5 million and mature on May 15, 2026.

Cash Flow Generation:

• Operating Cash Flow: $66.5 million (2024), a decrease from $100.6 million in 2023.
• Free Cash Flow: Approximately $60.1 million (2024), calculated as operating cash flow less capital expenditures.

Operational Excellence

Production & Service Model: Dynavax Technologies Corporation manufactures the hepatitis B surface antigen (HBsAg) for HEPLISAV-B at its Dynavax GmbH facility in Düsseldorf, Germany. The company relies on third parties for the combination of the oligonucleotide and antigens, and for formulation, fill, and finish services. It has limited experience in manufacturing commercial quantities of the pre-filled syringe presentation of HEPLISAV-B and relies on a single contract manufacturer for this.

Supply Chain Architecture:

• Key Suppliers & Partners:
  • Oligonucleotide Production: Relies on a limited number of suppliers for oligonucleotides for development and commercialization. A single supplier produces CpG 1018 adjuvant for HEPLISAV-B and collaborators. A second supplier for CpG 1018 adjuvant for the COVID business was qualified in 2021.
  • Formulation, Fill & Finish: Baxter Pharmaceutical Solutions LLC provides formulation, fill, and finish services for HEPLISAV-B. Dynavax Technologies Corporation is obligated to purchase an annual minimum number of batches through December 31, 2029, with aggregate minimum commitments of $17.0 million within the next 12 months and $55.4 million beyond the next 12 months as of December 31, 2024.
  • CpG 1018 Adjuvant Manufacturing: Nitto Denko Avecia Inc. (Avecia) manufactures and supplies CpG 1018 adjuvant. Dynavax Technologies Corporation is obligated to purchase all annual volume requirements of CpG 1018 adjuvant from Avecia up to a specified production capacity, with an aggregate minimum commitment of $8.2 million within the next 12 months as of December 31, 2024.

Facility Network:

• Manufacturing: Dynavax GmbH facility in Düsseldorf, Germany (75,727 square feet, leased until December 31, 2031).
• Research & Development: Research and development activities are conducted, with costs incurred for preclinical and clinical programs.
• Distribution: Relies on wholesalers and specialty distributors in the United States and a single distributor in Germany for HEPLISAV-B.

Operational Metrics: HEPLISAV-B cost of sales decreased by 1% in 2024 compared to 2023, primarily due to lower per-unit manufacturing costs resulting from previous process improvements and lower comparative one-time charges, partially offset by increased sales volume.

Market Access & Customer Relationships

Go-to-Market Strategy:

• Distribution Channels:
  • Direct Sales: A field sales force of approximately 103 people targets key customers in the United States, including independent hospitals and clinics, integrated delivery networks, dialysis centers, public health clinics and prisons, the U.S. Department of Defense, the U.S. Department of Veterans Affairs, and retail pharmacies.
  • Channel Partners: Bavarian Nordic is the commercialization partner for marketing and distribution of HEPLISAV-B in Germany.
  • Digital Platforms: The company employs innovative marketing campaigns targeting consumers and healthcare providers to increase awareness and demand for HEPLISAV-B.

Customer Portfolio:

• Enterprise Customers: In 2024, the three largest customers for HEPLISAV-B accounted for 30%, 21%, and 19% of total HEPLISAV-B net product revenue, respectively. Sales in Germany are made to one distributor.
• Customer Concentration: The company's accounts receivable balance is primarily from product sales, with three customers collectively representing approximately 97% of the HEPLISAV-B trade receivable balance as of December 31, 2024.

Geographic Revenue Distribution:

• United States: $273.6 million (98.7% of total revenue in 2024), primarily from HEPLISAV-B product sales and the U.S. Department of Defense agreement.
• Non-United States: $3.6 million (1.3% of total revenue in 2024), primarily from HEPLISAV-B product sales in Germany.

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition, and a strong emphasis on proprietary products. The global shingles vaccine market was over $4.0 billion in 2024.

Competitive Positioning Matrix:

Direct Competitors

Primary Competitors:

• Hepatitis B Vaccines: Engerix-B (GlaxoSmithKline plc), Recombivax-HB (Merck & Co.), Twinrix (GlaxoSmithKline plc), PreHevbrio (VBI Vaccines Inc.).
• Shingles Vaccine Candidates: Pfizer, BioNTech SE, Curevo Vaccine, Moderna, Inc. (competing with Shingrix).
• General Vaccine & Adjuvant Developers: GlaxoSmithKline plc, Pfizer, Inc., Sanofi S.A., Merck & Co., Bavarian Nordic A/S, Emergent BioSolutions, Inc., Novavax, Inc., Medicago Inc., Valneva, AstraZeneca plc, Moderna, Inc., Johnson & Johnson, VBI Vaccines Inc., BioNTech SE, and Curevo Vaccine.

Emerging Competitive Threats: The company faces increasing vaccine skepticism and disinformation, which may negatively impact market acceptance. New entrants, disruptive technologies, and alternative solutions also pose competitive threats.

Competitive Response Strategy: Dynavax Technologies Corporation's strategy includes leveraging HEPLISAV-B's two-dose, one-month regimen advantage, advancing a differentiated vaccine pipeline using CpG 1018 adjuvant, and implementing innovative marketing campaigns.

Risk Assessment Framework

Strategic & Market Risks

Market Dynamics: The timing of uptake and distribution efforts for HEPLISAV-B is unpredictable due to significant competition. Vaccine skepticism and disinformation campaigns may negatively impact market acceptance and sales growth. Technology Disruption: All clinical programs, including HEPLISAV-B, rely on oligonucleotide Toll-like Receptor (TLR) agonists. Serious adverse events related to TLR agonists could necessitate delays, discontinuation, or modification of clinical trials, or a reevaluation of strategic alternatives. Customer Concentration: As of December 31, 2024, three customers collectively represented approximately 97% of the HEPLISAV-B trade receivable balance. Sales in Germany are to a single distributor.

Operational & Execution Risks

Supply Chain Vulnerabilities: The company relies on its facility in Düsseldorf, Germany, and third parties for manufacturing processes. It depends on a limited number of suppliers for oligonucleotides, with a single supplier for CpG 1018 adjuvant for HEPLISAV-B and collaborators. A single contract manufacturer is used for the pre-filled syringe presentation of HEPLISAV-B, and qualifying a second source could take over a year. Capacity Constraints: Financial commitments for manufacturing and supply capacity, including minimum purchase commitments and prepayments, might outpace actual demand, potentially leading to unrecovered costs or write-offs. Clinical Trial Vulnerabilities: Clinical trials are expensive, time-consuming, and have uncertain outcomes. Delays or failures can arise from scheduling conflicts, enrollment difficulties, regulatory approvals, unexpected adverse events, or supply shortages. International Operations: Expanding HEPLISAV-B or other product candidates internationally involves substantial costs, personnel burdens, and risks related to varying regulatory requirements, distribution, marketing, intellectual property protection, pricing, and geopolitical factors.

Financial & Regulatory Risks

Demand Volatility: HEPLISAV-B product revenue is subject to seasonal variations, typically lower in the fourth quarter due to holiday schedules and increased focus on respiratory disease vaccines. CpG 1018 adjuvant revenue is highly dependent on collaborators' ability to commercialize their vaccines. Foreign Exchange: Operations in Germany, India, and Italy expose the company to foreign exchange rate fluctuations, primarily between Euros and U.S. dollars. Credit & Liquidity: Dynavax Technologies Corporation has an accumulated deficit of $903.3 million as of December 31, 2024. Servicing the $225.5 million Convertible Notes due in 2026 requires significant cash. The company may require substantial additional capital if product sales revenue is insufficient. Regulatory & Compliance Risks: Ongoing U.S. Food and Drug Administration, European Union, and United Kingdom post-marketing obligations for HEPLISAV-B (e.g., observational studies, pregnancy registry) may incur significant expenses. Non-compliance with current Good Manufacturing Practices, Good Clinical Practices, or other regulatory requirements can lead to penalties, product withdrawal, or marketing restrictions. The company is subject to extensive healthcare fraud and abuse laws (e.g., Anti-Kickback Statute, False Claims Act, HIPAA, Physician Payments Sunshine Act) and government price reporting requirements.

Geopolitical & External Risks

Geopolitical Exposure: International operations in Germany, India, and Italy expose the company to regional and geopolitical risks. As a U.S. Department of Defense contractor, the company is subject to International Traffic in Arms Regulations compliance. Natural Disasters & Health Epidemics: Business operations are vulnerable to interruptions from natural disasters (e.g., earthquakes, wildfires in California), health epidemics (e.g., COVID-19 impact on vaccine utilization), war, terrorism, bank failures, and geopolitical unrest. The company does not carry earthquake insurance and has limited business interruption insurance. Cybersecurity: Increasing reliance on complex information technology systems makes the company vulnerable to cybersecurity threats (e.g., malicious intrusion, ransomware, social engineering). Reliance on third-party service providers adds to this risk. Evolving data privacy laws (e.g., HIPAA, EU General Data Protection Regulation, UK General Data Protection Regulation, California Consumer Privacy Act) impose stringent requirements, with potential for significant fines, litigation, and reputational harm from breaches or non-compliance.

Innovation & Technology Leadership

Research & Development Focus:

• Core Technology Areas: Dynavax Technologies Corporation's research and development is centered on its CpG 1018 adjuvant, a proprietary Toll-like Receptor 9 (TLR9) agonist. This technology is designed to stimulate specific immune system cells, driving T Helper 1 (Th1) immune responses and potent, durable antibody production, with a favorable tolerability profile.
• Innovation Pipeline: The company is advancing vaccine candidates for shingles (Z-1018) and plague (rF1V with CpG 1018), and exploring a four-dose HEPLISAV-B regimen for adults on hemodialysis. Additional vaccine programs are in preclinical development.

Intellectual Property Portfolio:

• Patent Strategy: As of December 31, 2024, the intellectual property portfolio included over 20 issued United States patents, over 45 granted foreign patents, and over 130 additional pending United States non-provisional and foreign patent applications.
  • HEPLISAV-B: Three issued United States patents related to certain uses expire in 2032. The vaccine has no composition of matter patent protection.
  • Shingles Vaccine: 32 pending United States and foreign patent applications.
  • COVID-19 Vaccines: Four issued United States and foreign patents and 53 pending United States non-provisional and foreign patent applications, some co-owned with Valneva Austria GmbH, Medigen Vaccine Biologics Corporation, or Colorado State University Research Foundation.
  • Plague Vaccine: One pending United States patent application, co-owned with The Government of the United States, as Represented by the Secretary of the Army.
• Licensing Programs: The company relies on trade secrets and confidentiality agreements to protect proprietary know-how.
• IP Litigation: The company may become involved in disputes and litigation to enforce or defend its intellectual property rights, which could be costly and time-consuming.

Technology Partnerships:

• Strategic Alliances: Collaboration with the U.S. Department of Defense for the plague vaccine candidate.
• Research Collaborations: Engaged in clinical and preclinical collaborations with third-party organizations to evaluate CpG 1018 adjuvanted vaccine product candidates for influenza, other infectious diseases, and COVID-19.

Leadership & Governance

Executive Leadership Team

Leadership Continuity: The company depends on its senior executive officers and other key scientific personnel, and the loss of one or more key members could adversely affect commercial and business efforts.

Board Composition: The Board of Directors addresses cybersecurity risk management as part of its general oversight function. The Audit Committee reviews and discusses cybersecurity risk assessment and management processes with senior management.

Human Capital Strategy

Workforce Composition:

• Total Employees: 405 as of December 31, 2024.
• Geographic Distribution: 260 employees in the United States (including 103 field sales team members) and 145 employees in Düsseldorf, Germany.
• Skill Mix: Many employees hold advanced degrees, including Masters, Pharm.D., Ph.D., M.D., or J.D.

Talent Management:

• Acquisition & Retention: The regrettable turnover rate for 2024 was 6% in the United States and 5% in Düsseldorf. Average employee tenure is 3.7 years in the United States and 6.1 years in Düsseldorf. The company's remote-first working environment in the United States is considered a recruiting and retention tool. Compensation programs include base salary, annual cash bonuses or semi-annual sales incentive bonuses, comprehensive benefits, and equity compensation for all employees.
• Diversity & Development: The company performs annual performance reviews and seeks employee feedback through surveys. In 2024, 29 leaders and key contributors completed a leadership development program, adding to the 32 participants from the prior year. Extensive employee training programs cover business ethics, compliance, anti-corruption, and cybersecurity.

Diversity & Development: Dynavax Technologies Corporation was certified as a Great Place To Work for the second consecutive year in 2024 and was named by Fortune as one of the Best Places to Work in small to medium-sized biotech companies in the United States.

Environmental & Social Impact

Environmental Commitments:

• Climate Strategy: The company's headquarters is in a "Gold" level LEED certified building. A transition to a largely virtual environment has helped reduce congestion and pollution, and the relatively small headquarters space (approximately 8,000 square feet) has further reduced its carbon footprint.
• Supply Chain Sustainability: The company participates in its building's active recycling program.
• Environmental Expenditures: Expenditures for compliance with environmental laws are not expected to have a material effect on future results of operations.

Social Impact Initiatives: The company is committed to community outreach and engagement, with bettering public health as a core mission.

Business Cyclicality & Seasonality

Demand Patterns:

• Seasonal Trends: HEPLISAV-B product revenue is subject to seasonal variations, typically lower in the fourth quarter of the fiscal year compared to the third quarter. This is attributed to holiday schedules and increased focus by healthcare providers on respiratory disease vaccines, including those for influenza, COVID-19, and respiratory syncytial virus, during the fall and winter months.

Planning & Forecasting: Not explicitly detailed.

Regulatory Environment & Compliance

Regulatory Framework:

• Industry-Specific Regulations: Dynavax Technologies Corporation is subject to extensive requirements from the U.S. Food and Drug Administration, the European Medicines Agency, the European Commission, and the UK Medicines and Healthcare products Regulatory Agency concerning clinical development, pre-market approval, manufacturing, labeling, marketing, promotion, pricing, import, export, storage, and distribution of biopharmaceuticals.
• International Compliance: The company must comply with the European Union's Clinical Trials Regulation and various Marketing Authorization procedures (centralized, decentralized, mutual recognition). In the United Kingdom, it adheres to the Human Medicines Regulations and new pathways like the Innovative Licensing and Access Pathway.

Trade & Export Controls:

• Export Restrictions: As a U.S. Department of Defense contractor, the company is subject to additional administrative burdens and control requirements, including maintaining an International Traffic in Arms Regulations compliance program.

Legal Proceedings:

• Material Litigation: The company is not currently aware of any material legal proceedings.
• Class Action Law Suit: A putative class action complaint (Ignasiak v. Dynavax Technologies Corporation et al., C.A. No. 2023-1219-JTL) regarding a limited-duration stockholder rights plan was resolved in February 2025. An amendment was made to the Rights Agreement, and the company agreed to pay $155,000 in attorneys’ fees and expenses.

Tax Strategy & Considerations

Tax Profile:

• Effective Tax Rate: 11.5% for the year ended December 31, 2024, compared to -46.3% for the year ended December 31, 2023. The income tax expense is primarily comprised of state and foreign income tax expense.
• Geographic Tax Planning: The company is subject to income tax examinations for U.S. federal and state income taxes from 2001 forward, in Germany from 2020 forward, in India from 2021 forward, and in Italy from 2021 forward.
• Tax Reform Impact: As of December 31, 2024, the company had federal net operating loss (NOL) carryforwards of approximately $0.4 million expiring in 2025, and $293.1 million (post-2017) that do not expire but are limited to 80% of taxable income. State NOL carryforwards totaled approximately $262.9 million, expiring between 2025 and 2041. Federal research and development tax credits of approximately $26.5 million expire between 2025 and 2044, while California state research and development tax credits of approximately $21.8 million do not expire. A full valuation allowance is maintained against net deferred tax assets, as realization is not considered more likely than not.

Insurance & Risk Transfer

Risk Management Framework:

• Insurance Coverage: Dynavax Technologies Corporation maintains limited clinical trial liability and umbrella insurance coverage for its clinical trials and product liability insurance for HEPLISAV-B.
• Risk Transfer Mechanisms: The company does not carry earthquake insurance for earthquake-related losses and has only limited business interruption insurance.